PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

Career Paths and Title Inflation

Are Outcomes-Based Deals Just a Band-Aid for High Drug Prices?

Restoring Pharma's Reputation
Sales and Marketing
Understanding and Leveraging Key Online Influencers
In today's reality, where we live online just as much as offline, pharma marketers cannot just rely on the traditional KOL model to understand the mindset of the marketplace, write Francesco Lucarelli and Colin Foster
… /Read more/
Advertisement
Managing Global Regulatory Complexity: Clinical Trial Transparency, Reporting and Real-time Data Driven Compliance
On Demand
Learn more
Sales and Marketing
Will AI Kill the Pharma Rep?
By the end of 2020, it is predicted that AI will create more jobs than it is taking. Should reps be concerned, asks David Logue
… /Read more/
Calendar
/ September 10–11: 5th Annual Bio/Pharmaceutical Product Launch Summit /
Cambridge, MA
/ September 12– 13: 5th Annual Compliance Congress for Specialty Products /
Cambridge, MA
/ September 18–19: 5th Edition Drug Pricing Transparency Congress /
Philadelphia, PA.
/ September 24–25: 3rd Annual Finance & Accounting for Bioscience Companies /
Cambridge, MA
/ October 8–9: Life Sciences West Coast Compliance Congress /
San Francisco, CA,
/ November 13–14: 6th Annual Global Compliance Congress /
London, UK
/ December 11: eyeforpharma Awards 2019 /
Philadelphia, PA.
Opinion
A Bold Deal Could Help Trump Administration End HIV in America
The US could theoretically treat every single American living with HIV without spending an extra dollar on drugs. And President Trump can broker a deal to do it, write Mylan's Anil Soni and Ya'ir Aizenman
… /Read more/
 
Opinion
Building Healthcare Organizations That Put People First
Every healthcare company should be striving to identify better ways to ensure patients and consumers inspire every decision they make, writes Joanne Waldstreicher, Johnson & Johnson's Chief Medical Officer.
… /Read More/
 
Regulatory
Drug Importing Back on Center Stage
HHS, FDA back Trump back cheaper foreign drugs to cut pharma costs. Jill Wechsler reports
… /Read More/
Audio
The Pharm Exec Podcast: Differentiate Yourself in Crowded Therapeutic Areas
Pharm Exec sits down with Mark Velleca, CEO of G1 Therapeutics, who talks about how he differentiates himself in the oncology field and why he considers G1 Therapeutics an "old school company"
… /Click here to listen/
Industry update
//CURE Pharmaceutical (Oxnard, CA) announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. // Codexis (Redwood City, CA) named Ross Taylor as Senior Vice President and Chief Financial Officer, effective August 19, 2019. // Editas Medicine (Cambridge, MA) announced that its Board of Directors unanimously appointed Cynthia (Cindy) Collins, a 30-plus year industry veteran currently serving as the company's interim CEO, as President and Chief Executive Officer. // SQZ Biotechnologies (Watertown, MA) announced the appointment of Teri Loxam as Chief Financial Officer. // Adrian Rawcliffe will assume the role of CEO of Adaptimmune (Philadelphia, PA and Oxford, UK) from September 1, 2019. The company has also promoted John Lunger to Chief Patient Supply Officer. Former President R&D, Rafael Amado, left the company on August 12. Adaptimmune is recruiting a Chief Medical Officer and a Chief Financial Officer. //
advertise with us / print subscribe / digital subscribe / visit pharmexec.com